In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial-Reference-Cited by-同舟云学术

In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial

Published:2018-03-19 Issue:5 Volume:7 Page:e1424673
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Adotevi O.¹²,Godet Y.¹,Galaine J.¹,Lakkis Z.³^ORCID,Idirene I.¹,Certoux J. M.¹,Jary M.¹²,Loyon R.¹,Laheurte C.¹⁴⁵,Kim S.²,Dormoy A.⁶,Pouthier F.⁶,Barisien C.⁶,Fein F.⁷,Tiberghien P.¹,Pivot X.¹²,Valmary-Degano S.¹⁸,Ferrand C.¹,Morel P.⁶,Delabrousse E.⁹,Borg C.¹²

Affiliation:

1. University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France

2. University Hospital of Besançon, Department of Medical Oncology, F-25000 Besançon, France

3. University Hospital of Besançon, Department of Gastrointestinal and liver surgery, F-25000 Besançon, France

4. Etablissement Français du Sang Bourgogne Franche-Comté, plateforme de BioMonitoring, F-25000 Besançon, France

5. INSERM CIC-1431, University Hospital of Besançon, Clinical Investigation Center in Biotherapy, F-25000, Besançon, France

6. Etablissement Français du Sang Bourgogne Franche-Comté, F-25000 Besançon, France

7. University Hospital of Besançon, Department of Gastroenterology, F-25000 Besançon, France

8. University Hospital of Besançon, Department of Pathology, F-25000 Besançon, France

9. University Hospital of Besançon, Department of Radiology, F-25000, Besançon, France

Funder

French National Cancer Institute

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1424673

Reference45 articles.

1. Functions of natural killer cells

2. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs

3. Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming

4. KIR and KIR ligand polymorphism: a new area for clinical applications?

5. NK Cells in Therapy of Cancer

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploiting the immune system in hepatic tumor targeting: Unleashing the potential of drugs, natural products, and nanoparticles;Pathology - Research and Practice;2024-04

2. Development of NK cell-based cancer immunotherapies through receptor engineering;Cellular & Molecular Immunology;2024-03-05

3. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy;Frontiers in Immunology;2023-11-24

4. Therapeutic Anti-KIR Antibody of 1–7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom;International Journal of Molecular Sciences;2023-09-16

5. Contribution of natural killer cells in innate immunity against colorectal cancer;Frontiers in Oncology;2023-01-04